Show simple item record

Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

dc.contributor.authorYarman, Sema
dc.contributor.authorSelcukbiricik, Ozlem Soyluk
dc.contributor.authorTanrikulu, Seher
dc.contributor.authorDogansen, Sema Ciftci
dc.date.accessioned2021-03-02T21:45:35Z
dc.date.available2021-03-02T21:45:35Z
dc.date.issued2016
dc.identifier.citationDogansen S. C. , Selcukbiricik O. S. , Tanrikulu S., Yarman S., "Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?", PITUITARY, cilt.19, sa.3, ss.303-310, 2016
dc.identifier.issn1386-341X
dc.identifier.otherav_08beaab0-fbe5-4239-9a36-fe25a6726db8
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/11688
dc.identifier.urihttps://doi.org/10.1007/s11102-016-0708-3
dc.description.abstractPurpose The aim of the study was to assess the effect of dopamine agonist (DA) withdrawal, the current recurrence rate of hyperprolactinemia, and possible factors that predict recurrence in patients with prolactinoma.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.titleWithdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
dc.typeMakale
dc.relation.journalPITUITARY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume19
dc.identifier.issue3
dc.identifier.startpage303
dc.identifier.endpage310
dc.contributor.firstauthorID232655


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record